Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P)

• Published in: BJU international 2024
• Main Authors: Löffeler, Sven, Bertilsson, Helena Maria, Müller, Christoph Rainer, Aas, Kirsti, Haugnes, Hege Sagstuen, Aksnessæther, Bjørg Yksnøy, Pesonen, Maiju, Thon, Kristian, Tandstad, Torgrim, Murtola, Teemu, Poulsen, Mads Hvid Aaberg, Nordstrøm, Tobias, Vigmostad, Maria Nyre, Ottosson, Fredrik, Holmsten, Karin, Christiansen, Ola B, Slaaen, Marit, Haug, Erik Skaaheim, Storås, Anne Holck, Asphaug, Lars, Rannikko, Antti, Brasso, Klaus
• Format: Article
• Language: Norwegian
• ISSN: 1464-4096; 1464-410X

Background Older men (aged ≥75 years) with high risk, non-metastatic prostate cancer (PCa) are increasingly treated with curative therapy (surgery or radiotherapy). However, it is unclear if curative therapy prolongs life and improves health-related quality of life (HRQoL) in this age group compared to conservative therapy, which has evolved considerably during the last decade. Study Design The Scandinavian Prostate Cancer Group (SPCG) 19/Norwegian Get-Randomized Research Group-Prostate (GRand-P) is a randomised, two-armed, controlled, multicentre, phase III trial carried out at study centres in Norway, Denmark, Finland, and Sweden. Endpoints The primary endpoints are overall survival and HRQoL (burden of disease scale, European Organisation for the Research and Treatment of Cancer [EORTC] Elderly Cancer patients). Secondary endpoints are PCa-specific survival, metastasis-free survival, role-functioning scale (EORTC quality of life questionnaire 30-item core), urinary irritative/obstructive scale (26-item Expanded Prostate Cancer Index Composite [EPIC-26]), bowel scale (EPIC-26), intervention-free survival, PCa morbidity, use of secondary and tertiary systemic therapies, mean quality-adjusted life-years (QALYs), and mean total healthcare costs. Patients and Methods A total of 980 men (aged ≥75 years) with non-metastatic, high-risk PCa will initially be screened with Geriatric 8 (G8) health status screening tool and Mini-COG© brief cognitive test. Participants identified by G8 as ‘fit’ or ‘frail’ will be randomised (ratio 1:1) to either immediate curative therapy (radiotherapy or prostatectomy) or conservative therapy (endocrine therapy or observation). Participants who are unable or unwilling to participate in randomisation will be enrolled in a separate observation group. Randomised patients will be followed for 10 years.